233 related articles for article (PubMed ID: 15562827)
21. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies.
Shah OJ; Wang Z; Hunter T
Curr Biol; 2004 Sep; 14(18):1650-6. PubMed ID: 15380067
[TBL] [Abstract][Full Text] [Related]
22. Tumour suppressors hamartin and tuberin: intracellular signalling.
Krymskaya VP
Cell Signal; 2003 Aug; 15(8):729-39. PubMed ID: 12781866
[TBL] [Abstract][Full Text] [Related]
23. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.
Kenerson HL; Aicher LD; True LD; Yeung RS
Cancer Res; 2002 Oct; 62(20):5645-50. PubMed ID: 12384518
[TBL] [Abstract][Full Text] [Related]
24. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.
Fingar DC; Blenis J
Oncogene; 2004 Apr; 23(18):3151-71. PubMed ID: 15094765
[TBL] [Abstract][Full Text] [Related]
25. Critical role of T-loop and H-motif phosphorylation in the regulation of S6 kinase 1 by the tuberous sclerosis complex.
Shah OJ; Hunter T
J Biol Chem; 2004 May; 279(20):20816-23. PubMed ID: 14993219
[TBL] [Abstract][Full Text] [Related]
26. Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration.
Astrinidis A; Cash TP; Hunter DS; Walker CL; Chernoff J; Henske EP
Oncogene; 2002 Dec; 21(55):8470-6. PubMed ID: 12466966
[TBL] [Abstract][Full Text] [Related]
27. mTOR cascade activation distinguishes tubers from focal cortical dysplasia.
Baybis M; Yu J; Lee A; Golden JA; Weiner H; McKhann G; Aronica E; Crino PB
Ann Neurol; 2004 Oct; 56(4):478-87. PubMed ID: 15455405
[TBL] [Abstract][Full Text] [Related]
28. Expression, purification, crystallization and preliminary structural characterization of the GTPase domain of human Rheb.
Yu Y; Chang Y; Li S; Hu H; Huang Q; Ding J
Acta Crystallogr D Biol Crystallogr; 2004 Oct; 60(Pt 10):1883-7. PubMed ID: 15388940
[TBL] [Abstract][Full Text] [Related]
29. Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/- cells.
Uhlmann EJ; Apicelli AJ; Baldwin RL; Burke SP; Bajenaru ML; Onda H; Kwiatkowski D; Gutmann DH
Oncogene; 2002 Jun; 21(25):4050-9. PubMed ID: 12037687
[TBL] [Abstract][Full Text] [Related]
30. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
Roux PP; Ballif BA; Anjum R; Gygi SP; Blenis J
Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13489-94. PubMed ID: 15342917
[TBL] [Abstract][Full Text] [Related]
31. Rheb fills a GAP between TSC and TOR.
Manning BD; Cantley LC
Trends Biochem Sci; 2003 Nov; 28(11):573-6. PubMed ID: 14607085
[TBL] [Abstract][Full Text] [Related]
32. TSC2: filling the GAP in the mTOR signaling pathway.
Li Y; Corradetti MN; Inoki K; Guan KL
Trends Biochem Sci; 2004 Jan; 29(1):32-8. PubMed ID: 14729330
[TBL] [Abstract][Full Text] [Related]
33. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination.
Benvenuto G; Li S; Brown SJ; Braverman R; Vass WC; Cheadle JP; Halley DJ; Sampson JR; Wienecke R; DeClue JE
Oncogene; 2000 Dec; 19(54):6306-16. PubMed ID: 11175345
[TBL] [Abstract][Full Text] [Related]
34. VPS34 regulates TSC1/TSC2 heterodimer to mediate RheB and mTORC1/S6K1 activation and cellular transformation.
Mohan N; Shen Y; Dokmanovic M; Endo Y; Hirsch DS; Wu WJ
Oncotarget; 2016 Aug; 7(32):52239-52254. PubMed ID: 27409169
[TBL] [Abstract][Full Text] [Related]
35. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho.
Lamb RF; Roy C; Diefenbach TJ; Vinters HV; Johnson MW; Jay DG; Hall A
Nat Cell Biol; 2000 May; 2(5):281-7. PubMed ID: 10806479
[TBL] [Abstract][Full Text] [Related]
36. Niban gene is commonly expressed in the renal tumors: a new candidate marker for renal carcinogenesis.
Adachi H; Majima S; Kon S; Kobayashi T; Kajino K; Mitani H; Hirayama Y; Shiina H; Igawa M; Hino O
Oncogene; 2004 Apr; 23(19):3495-500. PubMed ID: 14990989
[TBL] [Abstract][Full Text] [Related]
37. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
Tee AR; Fingar DC; Manning BD; Kwiatkowski DJ; Cantley LC; Blenis J
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13571-6. PubMed ID: 12271141
[TBL] [Abstract][Full Text] [Related]
38. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex.
Brugarolas J; Lei K; Hurley RL; Manning BD; Reiling JH; Hafen E; Witters LA; Ellisen LW; Kaelin WG
Genes Dev; 2004 Dec; 18(23):2893-904. PubMed ID: 15545625
[TBL] [Abstract][Full Text] [Related]
39. Tuberous sclerosis genes regulate cellular 14-3-3 protein levels.
Hengstschläger M; Rosner M; Fountoulakis M; Lubec G
Biochem Biophys Res Commun; 2003 Dec; 312(3):676-83. PubMed ID: 14680818
[TBL] [Abstract][Full Text] [Related]
40. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner.
Castro AF; Rebhun JF; Clark GJ; Quilliam LA
J Biol Chem; 2003 Aug; 278(35):32493-6. PubMed ID: 12842888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
